Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, discusses a study that explored methylation as a predictor for response in ovarian cancer.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More